QS Research · Michael Burry's Scion Capital analyst template · 2006
EXAGEN INC. (XGN)
As of 2026-11-17 · 13/15 boxes filled from SEC filings and market data
Report price $3.77 (close 2026-11-16); latest close $3.61 (2026-11-20), -4.2% since the report; figures re-marked at the latest close
Conclusion: PASS
Conviction low · base case none · downside -28% · upside +20%
At today’s price the market pays EV/Sales of 1.29x and P/S of 1.33x, essentially the company’s own 1.3x five-year median, for a business with EBIT of -$14.5M, EBITDA of -$12.0M, net income of -$18.2M and free cash flow of -$13.0M TTM; ROIC is -79.4% against a 14.8% WACC. The call is PASS because the quality gate fails—no moat is evidenced, ROIC is below WACC and the FCF yield is -13.5%—and because no independent multiple supports a base case. There is no base case: no comparable peer multiple sets one, and a base at the company’s own multiple today would be today’s price by construction. The downside is -31.1% to $2.60, on -20.0% sales at a compressed EV/Sales of 1.1x (today 1.29x). The upside is +14.6% to $4.32, on +15% sales at today’s EV/Sales of 1.29x. The label therefore rests on those two cases alone.
Key numbers
- Share price: $3.61
- Market cap: $92.1M
- Latest financial period: TTM to Sep 30, 2026
- Revenue (TTM): $72.3M
- FCF yield: -14.1%
- Price / book: 6.68x
- Earnings-quality flags (TTM): Mark-to-market on the company's own stock (warrants) $1.1M (6% of net income)
- Revenue growth (latest fiscal year): +19.7%
- ROIC (TTM): -79.4%
- WACC: 14.8%
- Economic profit spread: -94.3 pts
The 15 boxes
- ✓ 1. Long-form business notes
Exagen is a rheumatology-focused testing company whose revenue comes mainly from reimbursement for AVISE CTD, which was 91% of revenue in FY2025 and FY2024. FY2025 revenue was a record $66.6M, up 19.7% from FY2024, and XBRL shows revenue at $72.3M TTM to 2026-09-30, but operating income, net income and operating cash flow remain negative. The business changed from the FY2020 10-K's integrated testing-and-therapeutics model and ~5,000-rheumatologist target to a FY2025 testing-focused operational turnaround targeting ~6,000 rheumatologists, with losses still persistent.
- ✓ 2. Competitive advantage
No durable moat is visible. The 10-K names the traditional ANA/anti-dsDNA/C3/C4 workup and the existing infrastructures of ARUP, LabCorp, Mayo Clinic and Quest as the competition, and admits it has no contracts with significant private payors. Revenue grew from $42.0M in FY2020 to $72.3M in the TTM to 2026-09-30, yet operating income was negative in all seven periods on file and was still -$14.5M in the TTM, so growth has not turned into pricing power or operating leverage.
- ✓ 3. 10-Q takeaways
Q3 2026 revenue was $18.4 million, up 6.8% (7% in the release) on AVISE CTD test volume up ~2% and trailing-twelve-month ASP up $10 to $451, with gross margin 58.8% versus 58.4%. Growth is not yet dropping to operating profit: operating loss widened to $(4.4) million in Q3 2026 from $(3.1) million as SG&A rose 12.1% and a $587,000 IPR&D charge landed, while the smaller net loss ($(6.3) million versus $(7.1) million) was helped by a smaller warrant revaluation. Cash fell to $28.1 million at September 30, 2026 from $35.7 million a year earlier, partly offset by $6.7 million gross of ATM stock sold in the quarter; FY2026 revenue guidance is still $72-75 million.
- ✓ 4. Corporate governance
Filled; members read this box.
- ✓ 5. Overview of the prior 3 years of 8-K filings
Filled; members read this box.
- ✓ 6. Other significant filings
Filled; members read this box.
- ✓ 7. Chronology of significant news and events
Filled; members read this box.
- ✓ 8. Comparables valuation interpretation
Filled; members read this box.
- ✓ 9. Insider trading interpretation
Filled; members read this box.
- ○ 10. Earnings-call notes
- ✓ 11. Impression of the shareholder letter
Filled; members read this box.
- ○ 12. Scuttlebutt overview
- ✓ 13. Valuation and risk/reward summary
Filled; members read this box.
- ✓ 14. Current price suppression and potential catalysts
Filled; members read this box.
- ✓ 15. Conclusions
The call above.
Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.